Trial of Trastuzumab Deruxtecan in Previously Treated HER2
Status:
RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the good and bad effects of a drug called trastuzumab deruxtecan (T-DXd) in adult patients with metastatic HER2-negative breast cancer and which patients might benefit the most from T-DXd.